A dPCR-NIPT assay for detections of trisomies 21, 18 and 13 in a single-tube reaction-could it replace serum biochemical tests as a primary maternal plasma screening tool?

Table 7 Cost comparison of different strategies for screening fetal aneuploidies

Screen strategy¹	Sample number	1st screen				2nd screen		Total cost ($)
Screen strategy¹	Sample number	Method	$/Test²	Cost($)	HR case³	Method	Cost ($)	Total cost ($)
Existing CS	10,000	STB	53	530,000	1500	NGS-NIPT	855,000	1,385,000
NGS-NIPT	10,000	NGS-NIPT	570	5,700,000	–	–	–	5,700,000
Upgraded CS	10,000	dPCR-NIPT	100	1,000,000	486	NGS-NIPT	277,020	1,277,020

CS contingent strategy, NGS-NIPT used as first-tier screen method; 2. $/test, the average price per test reported for STB and NGS-NIPT, the price for dPCR NIPT is estimated; 3. HR case, the high risk cases identified by the respective CS and the number is calculated based on the false positive rate of 15% for existing CS and 4.86% for the upgraded CS

ISSN: 1479-5876